|
KMID : 0356719980140020173
|
|
Journal of the Korean Society of Coloproctology
1998 Volume.14 No. 2 p.173 ~ p.177
|
|
|
Toxicity Evaluation of Oral Adjuvant Chemotherapeutic Drug UFT in the Colorectal Cancer
|
|
Kim Jin-Cheon
Kim Chang-Nam
Kim Hee-Cheol
Yu Chang-Sik
Kim Byung-Sik
Lee Je-Hwan
Kim Woo-Kun
|
|
|
Abstract
|
|
|
The addition of Uracil to Tegafur of 5-fluorouracil(5-FU) precursor(Tegafur and Uracil in a molar ratio of 1：4) is known to enhance the antineoplastic effect of 5-FU. This oral regimen also reduces side-effects attributed to 5-FU catabolism. The
toxicity of UFT was evaluated in 61 patients with colorectal cancer who underwent curative surgery. All patients had advanced cancer requiring adjuvant chemotherpy, but their age(over 70 years-old) or general condition precluded intravenous systemic chemotherpy. Oral UFT (400 mg of tegafur, 4 tablet/day) was administered in divided doses every 12 hour for mean duration of 6.2 months(range, 1∼13 months). The toxicity mainly disclosed hematological, gastrointestinal and dermatological complications. Leukopenia(20%), anemia (11%), anorexia(11%), nausea and vomiting(10%), abdominal pain(8%) and cutaneous toxicity including erythema or pruritus(7%). However, severity of toxicity seemed to be mild within grade 1 or 2 and most of them revealed self-limiting. They were relieved by symptomatic treatment or several months of rest. The regimen was completely interrupted in 3 patients(4.9%) due to prolonged leukocytopenia or derangement of liver function. There was no mortality from surgery or any drug-related toxicity during study period. Conclusively, oral UFT can be administered safely on an outpatient basis without lethal toxicity requiring hospitalization. It can be applicable especially in the risk groups need systemic adjuvant chemotherapy after surgery.
|
|
|
KEYWORD
|
|
|
UFT, Toxicity, Colorectal cancer
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|